Head-to-head evidence
mesalamine (Asacol) vs Mesalamine (Pentasa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline
mesalamine (Asacol)
Marketed by AbbVie
NCT00073021 · Phase 3 · completed
The trial randomized and double-blinded participants and compared two Asacol doses in 268 patients with moderate disease analyzed for the primary endpoint. Its primary clinical and sigmoidoscopic treatment-success endpoint was met: 71.8% responded with 4.8 g/day versus 59.2% with 2.4 g/day (p=0.0357).
Mesalamine (Pentasa)
Marketed by Takeda Pharmaceutical Company and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mesalamine (Asacol)'s landscape · Mesalamine (Pentasa)'s landscape